Forest Labs Licenses Respiratory Drug from Glenmark
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 53 (Table of Contents)
Published: 4 Nov-2004
DOI: 10.3833/pdr.v2004.i53.757 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Glenmark Pharmaceuticals entered into licensing agreement with Forest Laboratories to grant the North-American rights to Glenmark’s oral PDE4 inhibitor, GRC 3386 that is phase I clinical trials for treating chronic obstructive pulmonary disorder (COPD) and asthma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS